

16. (Amended) An enteral formulation for nasogastric delivery as in claim 15

A2 wherein the non-starch polysaccharide is selected from the group consisting of inulin, pectin, chitin, β glucans, mucilages, agar, carageenans, alginates and gums including guar, arabic, xanthan, tragacanth, locust bean and psyllium.

39. (Amended) A method of elevating the level of a fatty acid in the colon of a

A3 human or animal, including the step of delivering a fatty delivery agent in a physiologically acceptable medium through a feeding tube to elevate the level of the fatty acid, the fatty acid delivery agent being a fatty acid covalently bonded to a carrier molecule by a bond hydrolysable in the colon to thereby release the fatty acid.

62. (New) An enteral formulation for nasogastric delivery as in claim 13 wherein

the non-starch polysaccharide is selected from the group consisting of inulin, pectin, chitin, β -glucans, mucilages, agar, carageenans, alginates, gums, cellulose, hemicellulose and oligosaccharide,

A4 the gum selected from the group including guar, arabic, xanthan, tragacanth, locust bean and psyllium,

the cellulose selected from the group including of celluloses derived from oat hull, soybeans and cereal bran, microcrystalline celluloses, methyl celluloses, hydroxypropylmethyl cellulose and carboxymethylcellulose,

the oligosaccharide selected from the group consisting of fructooligosaccharides, galactooligosaccharides, short chain amyloextrins and maltodextrins and modifications and derivatives thereof.

See the attached Appendix for the changes made to effect the above claims.